Enzo Biochem, Inc.
ENZ
$0.464
-$0.015-3.13%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -4.56% | 2.72% | 204.05% | 346.55% | 140.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.56% | 2.72% | 204.05% | 346.55% | 140.15% |
| Cost of Revenue | -12.46% | -11.39% | 215.47% | 504.22% | 125.78% |
| Gross Profit | 7.60% | 26.51% | 192.27% | 260.62% | 166.22% |
| SG&A Expenses | -36.49% | -24.81% | 184.21% | 188.31% | 69.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.80% | -20.65% | 1,395.23% | 481.13% | 85.29% |
| Operating Income | 58.90% | 50.00% | 39.94% | -1.21% | -44.35% |
| Income Before Tax | 71.54% | 60.77% | 34.16% | 1.25% | -8.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 71.54% | 60.77% | 34.16% | 1.25% | -8.43% |
| Earnings from Discontinued Operations | -131.47% | -135.89% | 396.60% | 507.62% | 1,040.18% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -193.96% | -228.54% | 198.15% | 192.41% | 191.46% |
| EBIT | 58.90% | 50.00% | 39.94% | -1.21% | -44.35% |
| EBITDA | 60.77% | 49.68% | 39.23% | -6.65% | -58.38% |
| EPS Basic | -189.14% | -224.04% | 198.79% | 192.83% | 191.56% |
| Normalized Basic EPS | 72.82% | 61.95% | 36.81% | 2.36% | -21.10% |
| EPS Diluted | -190.40% | -224.37% | 198.52% | 192.50% | 191.12% |
| Normalized Diluted EPS | 72.82% | 61.95% | 36.81% | 2.36% | -21.10% |
| Average Basic Shares Outstanding | 3.74% | 3.47% | 2.88% | 2.29% | 1.52% |
| Average Diluted Shares Outstanding | 3.74% | 3.47% | 2.88% | 2.29% | 1.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
